[Ip-health] Clarification on HAI's position on NCDs

Tim Reed Tim at haiglobal.org
Tue Sep 20 06:36:27 PDT 2011


Dear All,

 

Clarification on HAI's position on NCDs

 

Andrew Jack's article on the NCD summit focuses exclusively on HAI
Global's position regarding the need for affordable and available
generic essential medicines which are already on the market. The HAI NCD
briefing note speaks purposely on access to generic medicines for NCDs
such as cardiovascular disease, diabetes and asthma. It specifically
does not mention unmet medical need and new essential medicines which
are still under patent, and which, because of their price make them
unaffordable and out of reach. HAI's statement does not imply support
for the industry position on unmet medical need and 'new' essential
medicines.  It is perfectly possible that the motive of the IFPMA in
citing import tariffs, taxes, intermediaries' profits, regulatory
obstacles and weak health systems as barriers to access is to divert
attention from their poor record on patent monopolies on new therapies.
IFPMA should not hide behind the argument of known challenges in health
care while at the same time failing to do  a better job of making sure
people have access to new essential treatments at affordable prices.
Thus, HAI's position regarding the Doha Declaration and TRIPS
flexibilities remains consistent in that they are regarded as just as
relevant for unmet medical need for NCDS as they are for communicable
diseases. It is crucial that TRIPS flexibilities are used to provide
access to life saving and otherwise unaffordable medicines that remain
under patent. Moreover, HAI remains steadfast in its belief  in the need
for exploring alternative models of innovation that delink the cost of
R&D from the price of the product and thereby contribute to universal
access to innovative medicines now and in the future. As a result, HAI
believes that these two complementary approaches are necessary for
securing access on the one hand to off patent generics and on the other
to new drugs still under patent, and the issues should not be seen as
opposed which only serves to obscure the real argument.  

 

Tim Reed

 

 

Dr. Tim Reed

HAI Global

Overtoom 60/II

1054 HK Amsterdam

The Netherlands

Tel: +31 20 683 3684 

Fax: +31 20685 5002

Email: tim at haiweb.org <mailto:tim at haiweb.org> 

Website: http://www.haiweb.org <http://www.haiweb.org> 

 

Health Action International (HAI) is an independent, global network
working to increase access to essential medicines and improve their
rational use through research excellence and evidence-based advocacy.

 

Important Email Information:

The information contained in this email is confidential and may be
legally privileged.  It is intended solely for the addressee and is for
the exclusive use of the intended recipient(s). If you are not the
intended recipient(s), please note that any form of disclosure,
distribution, copying or use of this communication or the information in
it or in any attachments is strictly prohibited and may be unlawful. If
you are not the intended addressee, please contact the sender and
dispose of this e-mail immediately. Any opinions expressed are those of
the author, not of HAI.

 

 




More information about the Ip-health mailing list